Application of HPLC–ESI–ITMS in the quality control of carboxyterminal sequence confirmation for the recombinant DNA product Hirudin Variant 3
-
Add time:07/27/2019 Source:sciencedirect.com
In the present study, HPLC–ESI–IT (ion-trap) MS was used for carboxyterminal (C-terminal) amino acid sequence confirmation of intact recombinant Hirudin Variant 3 (HV3) and alkylated HV3. The C-terminal amino acid sequence of HV3 was determined by the use of carboxypeptidase P (CPP), and by the combined use of carboxypeptidase P and carboxypeptidase Y (CPY). The C-terminal amino acid sequence of alkylated HV3 with 1,4-dithiothreitol (DTT) reduction was also confirmed by the combined use of CPP and CPY (abbreviated to CPP-CPY). Up to 19 amino acid residues were confirmed in the nanomolar concentration range by analyzing the molecular weights of the truncated peptides of HV3. Another five amino acids were confirmed in the nanomolar concentration range of alkylated HV3 with DTT reduction. For sequencing alkylated HV3 with DTT reduction, HV3 reduced with DTT followed by alkylation with iodoacetamide. The reaction mixture, which included alkylated HV3, DTT, and iodoacetamide, was then directly sequenced without any further pre-treatment. The reaction was designed in a time-, and concentration-dependent manner to obtain the maximum sequence information. The results showed that HPLC–ESI–ITMS cannot only determine the C-terminal amino acid sequence of HV3, but also gives important information about the enzymatic degradation and subsequent release of the C-terminal amino acids of HV3.
We also recommend Trading Suppliers and Manufacturers of hirudin HV3 (cas 134289-40-0). Pls Click Website Link as below: cas 134289-40-0 suppliers
Prev:INHIBITION OF THROMBIN BY HIRUDIN GENETICALLY FUSED TO WILD-TYPE OR MUTANT ANTITHROMBIN
Next:High cell density cultivation of recombinant Escherichia coli for hirudin variant 1 production) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs08/03/2019
- Combined administration of barbourin–albumin and hirudin–albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta08/02/2019
- Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes08/01/2019
- Potential use of hirudin in diabetic cataract: A study of galactose mediated human lens epithelial cells injury07/31/2019
- Investigation on recombinant hirudin via oral route07/30/2019
- Intracellular GSH and ROS levels may be related to galactose-mediated human lens epithelial cell apoptosis: Role of recombinant hirudin variant III07/29/2019
- High cell density cultivation of recombinant Escherichia coli for hirudin variant 1 production07/28/2019
- INHIBITION OF THROMBIN BY HIRUDIN GENETICALLY FUSED TO WILD-TYPE OR MUTANT ANTITHROMBIN07/26/2019


